• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Jan. 29

Aurobindo Pharma Ltd (APL) has received one more approval from the US Food and Drug Administration (USFDA) for Cefadroxil capsules of 500 mg.

Cefadroxil is a first generation Cephalosporin antibiotic. It is used in a wide variety of bacterial infections, especially concerning respiratory, skin & soft tissue, and urinary tract. According to a press release from APL, the Cefadroxil 500 mg capsules commands a market of over $21 million in the US alone. For APL, a leading manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, Cefadroxil is the third approval from the USFDA in the cephalosporin range. It is also the company's 37th overall approval from the regulator, the press release added. The company has filed over 75 abbreviated new drug applications for the US alone and over 100 drug master files.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hansen to invest Rs 940 cr in Coimbatore facility

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line